Watson Laboratories, Inc. vs United Therapeutics Corp.

Order Granting Patent Owner's Motion to Expunge

Patent Owner's Motion to Expunge Under 37 C.F.R. Section 42.56

Termination Decision Document

Joint Request to Treat Settlement Agreement (Ex. 2212) as Business Confidential Information under 35 U.S.C. Section 317(b) and 37 U.S.C. Section 37 U.S.C. 42.74(c)

Settlement Agreement

Patent Owner Updated Exhibit List as of August 21, 2018

Joint Motion to Terminate Proceedings Pursuant to 35 U.S.C. Section 317

Petitioner's Updated Notice of Deposition of ROBERT ROSCIGNO

Petitioners¿¿¿ Notice Of Deposition Of Robert Roscigno

Petitioner's Notice of Deposition of Aaron Trippe

Petitioner's Third Set Of Objections To Patent Owner's Exhibits

Conduct of the Proceeding 37 C.F.R. § 42.5

Exhibit 3009

Supplemental Patent Owner Response

Second Declaration of Ms. Pilar Wyman

Second Declaration of Dr. Aaron Waxman

Declaration of Mr. Aaron Trippe

Curriculum vitae of Aaron Trippe

Transcript from May 24, 2018 Deposition of Dr. Maureen Donovan

British Library Catalog Search Results for "Cardiology" (accessed July 3, 2018)

FDA Ventavis Label under Action Date 8/24/2005 (accessed July 2, 2018)

Williamson, A.A., "Period or Comma? Decimal Styles over Time and Place," Science Editor 31(2):42-43 (2008)

The popup window resulting from the selection of the "EN" option in the "summary publ" menu of https://web.archive.org/web/20100818181435/http://ec.europa.eu/health/documents/community-register/html/h255.htm

The webpage at https://web.archive.org/web/*/http://ec.europa.eu/health/documents/community-register/2005/2005090510259/*

The new tab resulting from the selection of the "ENG" option in the "decision docs" menu and "annex" menu of http://ec.europa.eu/health/documents/community-register/html/h255.htm for procedure listed as having a "close date procedure" of 8/09/2005

The new tab resulting from the selection of the "ENG" option in the "summary publ" menu of http://ec.europa.eu/health/documents/community-register/html/h255.htm for procedure listed as having a "close date procedure" of 8/09/2005

The Wayback Machine results for the webpage at the new tab resulting from the selection of the "ENG" option in the "summary publ" menu of http://ec.europa.eu/health/documents/community-register/html/h255.htm

The webpage available at https://web.archive.org/web/20060613114419/http://europa.eu:80/documents/comm/index_en.htm (dated June 13, 2006)

The webpage located at https://web.archive.org/web/20060615002523/http://ec.europa.eu/comm/secretariat_general/regdoc/recherche.cfm?CL=en

British Library Catalog Entry for Circulation (accessed July 6, 2018)

British Library Catalog Search Results for "Cardiovascular system" (accessed July 3, 2018)

British Library Catalog Search Results for Dewey 616.1 (accessed July 3, 2018)

Merck Manual ¿¿¿ Professional Version ¿¿¿ Evaluation of the Pulmonary Patient (accessed July 6, 2018)

FDA Ventavis Label under Action Date 12/29/2004 (accessed July 2, 2018)

Additional Excerpts from Deposition of Dr. Maureen Donovan in Civil Action No: 3:15-cv-05723 PGS-LHG

"The Internet Archive Turns 20: A Behind The Scenes Look At Archiving The Web," retrieved from https://www.forbes.com/, accessed on June 19, 2018

The webpage "Alexa Crawls," retrieved from https://archive.org/details/alexacrawls, accessed on June 19, 2018

"About this capture" information for the .pdf located at https://web.archive.org/web/20040718112852/http://www.nebu-tec.de:80/PDF/GA_B_de.pdf

The webpage at https://web.archive.org/web/20130801000000*/http://ec.europa.eu/health/documents/community-register/

The webpage at https://web.archive.org/web/20131012140925/http://ec.europa.eu/health/documents/community-register/

The webpage at https://web.archive.org/web/20100815000000*/http://ec.europa.eu/health/documents/community-register/html/h255.htm

The webpage at https://web.archive.org/web/20100818181435/http://ec.europa.eu/health/documents/community-register/html/h255.htm

The Wayback Machine results for the webpage at popup window resulting from the selection of the "EN" option in the "summary publ" menu (EX. 2125)

The popup window resulting from the selection of the "EN" option in the "decision docs" menu and "annex" menu of https://web.archive.org/web/20100818181435/http://ec.europa.eu/health/documents/community-register/html/h255.htm

The webpage at http://ec.europa.eu/health/documents/community-register/html/h255.htm as accessed on June 29, 2018

The webpage available at https://web.archive.org/web/20140115000000*/https://ec.europa.eu/transparency/regdoc/index.cfm?fuseaction=home

The webpage available at https://web.archive.org/web/20140101160453/http://ec.europa.eu/transparency/regdoc/index.cfm?fuseaction=home

The webpage available at https://web.archive.org/web/20060513232957/http://ec.europa.eu/ (dated May 13, 2006)

The webpage available at https://web.archive.org/web/20060514064044/https://ec.europa.eu/index_en.htm (dated May 14, 2006)

The webpage available at https://web.archive.org/web/20060615094022/http://ec.europa.eu:80/comm/secretariat_general/regdoc/registre.cfm (dated June 15, 2006)

The webpage available at https://web.archive.org/web/20060920111254/http://ec.europa.eu/comm/secretariat_general/regdoc/registre.cfm?CL=en (dated September 20, 2006)

The webpage located at https://web.archive.org/web/20060615002523/http://ec.europa.eu:80/comm/secretariat_general/regdoc/liste.cfm?CL=en resulting from a search for "ventavis"

The webpage located at https://web.archive.org/web/*/http://ec.europa.eu:80/comm/secretariat_general/regdoc/*

The .pdf located at https://web.archive.org/web/20060920103705/http://ec.europa.eu/comm/secretariat_general/regdoc/rep/2/2006/EN/2-2006-737-EN-1-0.Pdf

The webpage located at https://web.archive.org/web/20060617112044/http://ec.europa.eu:80/comm/secretariat_general/regdoc/recherche.cfm?CL=fr

The webpage located at https://web.archive.org/web/20060615002523/http://ec.europa.eu:80/comm/secretariat_general/regdoc/liste.cfm?CL=en

The webpage located at https://web.archive.org/web/20060827110233/http://ec.europa.eu/comm/secretariat_general/regdoc/recherche.cfm?CL=da

The webpage located at https://web.archive.org/web/20060827112249/http://ec.europa.eu/comm/secretariat_general/regdoc/recherche.cfm?CL=it

Patent Owner Updated Exhibit List as of June 26, 2018

Transcript of teleconference between the parties and the Board, June 20, 2018

Decision Denying Patent Owner's Request for Rehearing

Notice of Service of Supplemental Evidence Under 37 C.F.R. Section 42.64

MODIFIED SCHEDULING ORDER

Granting Motion for Pro Hac Vice Recognition of Kurt A. Mathas 37. C.F.R. sec 42.10(c)

Motion to Seal 37 C.F.R. sec(s) 42.14 and 42.54

Andrew R. Sommer Winston & Strawn LLP

Patent Owner Updated Exhibit List as of May 15, 2018

Transcript of teleconference between the parties and the Board, May 10, 2018

Patent Owner's Notice of Deposition of Christopher Butler Under 37 C.F.R. Section 42.53

Patent Owner's Request for Rehearing under C.F.R. Section 42.71

Patent Owner's Second Notice of Deposition of Maureen Donovan, Ph.D. Under 37 C.F.R. Section 42.53

Petitioner's Second Set Of Objections To Patent Owner's Exhibits

ORDER Conduct of the Proceeding

Order - 37 C.F.R. 42.14 and 42.54

Decision - 37 C.F.R. 42.51(b)(2)

EXPUNGED

Exhibit 3006

Order - 37. C.F.R. ¿¿ 42.5; 37 C.F.R 42.123(a)

Order - 37 C.F.R. 42.5

Exhibit 3007

Patent Owner Response

Transcript from April 4, 2018 Deposition of Dr. Maureen Donovan, Part 2 of 2

Transcript from April 6, 2018 Deposition of Dr. DeForest McDuff, Part 3 of 3

Email Correspondence with Petitioner regarding Deposition of Christopher Butler

Listing of Issues and Supplements of Circulation Accessible on Circulation Website (accessed April 17, 2018)

U.S. 4,319,155 ("Nakai")

Declaration of Dr. Aaron Waxman

Curriculum vitae of Dr. Aaron Waxman

Mosby's Medical Dictionary. 7th ed. Mosby Elsevier, 2006 (excerpt)

Rau, J.L., "Design Principles of Liquid Nebulization Devices Currently in Use," Respir. Care, 47(11):1257-1275 (2002)

Atkins, P.J. & T.M. Crowder. "The Design and Development of Inhalation Drug Delivery Systems," Pharmaceutical Inhalation Aerosol Technology, 2nd Ed. (A.J. Hichey ed., CRC Press), Ch. 9 (2003)

Ventavis¿¿ Patient Brochure

EXPUNGED

Transcript from March 28, 2018 Deposition of Dr. Scott Bennett, Part 1 of 2

Transcript from March 28, 2018 Deposition of Dr. Scott Bennett, Part 2 of 2

Transcript from April 4, 2018 Deposition of Dr. Maureen Donovan, Part 1 of 2

Transcript from April 6, 2018 Deposition of Dr. DeForest McDuff, Part 1 of 3

Transcript from April 6, 2018 Deposition of Dr. DeForest McDuff, Part 2 of 3

Second Declaration of Dr. Richard Dalby

Leung, K, Louca E., & Coates, A. "Comparison of Breath-Enhanced to Breath-Actuated Nebulizers for Rate, Consistency, and Efficiency," Chest, 126(5):1619-1627 (2004)

Rau, J.L., Respiratory Care Pharmacology. 6th Ed. Mosby, 2002 (excerpt)

Declaration of Dr. Robert Roscigno

EXPUNGED

EXPUNGED

Letter from FDA confirming IND filing

EXPUNGED

Declaration of Dr. Jeffrey Stec

Curriculum vitae and Record of Prior Testimony of Dr. Jeffrey Stec

EXPUNGED

Classes of Heart Failure, American Heart Association (accessed April 19, 2017)

FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension, July 30, 2009

Voswinckel, R., et al., "Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension: Results from Randomized Controlled Pilot Studies," JACC, 48(6): 1672-1681(2006)

The World's Biggest Public Companies ¿¿¿ United Therapeutics, Forbes (accessed April 26, 2018)

America¿¿¿s Best Small Public Companies, Forbes (accessed April 26, 2018)

United Therapeutics Corp., Morningstar (accessed March 29, 2017)

EXPUNGED

Tyvaso¿¿: Just Prescribed (accessed April 5, 2018)

Fastest-Growing Companies, Fortune (accessed April 26, 2018)

EXPUNGED

2013 Marketing Plan, Internal

EXPUNGED

EXPUNGED

Frumkin L.R., "The Pharmacological Treatment of Pulmonary Arterial Hypertension" Pharmacol. Rev. 64:583-620 (2012)

Khaybullina D., et al., "Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension," Pharmacy and Therapeutics. 39(11):749-758

Actelion Delivers Outstanding 2014 Results, Actelion website (accessed April 26, 2018)

EXPUNGED

EXPUNGED

EXPUNGED

Gagnon, M-A & Lexchin, J. "The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States," PLoS Medicine. 5(1):epub (2008)

David & Stewart, "Commercial Success: Economic Principles Applied to Patent Litigation," Leonard G.K. & Stiroh L.J.(Ed.) Economic Approaches to Intellectual Property: Policy, Litigation, and Management, 196-207 (2005)

U.S. 8,410,121

U.S. 9,550,716

February 17, 2010 Withdrawal Letter

Tyvaso Marketing Plan, December 2010, Internal, Part 4 of 4

GlobalData Advanced Export - Pulmonary Arterial Hypertension, April 2017

St. Louis Federal Reserve, Consumer Price Index, https://fred.stlouisfed.org/series/CPIAUCSL (accessed April 5, 2017)

Bloomberg L.P. WACC Report for UTHR (accessed March 14, 2017)

EXPUNGED

EXPUNGED

McDuff R.D. et al., "Thinking Economically about Commercial Success," Landslide Magazine 9(4) (2017)

Grabowski H. & Vernon J. "The Distribution of Sales Revenue from Pharmaceutical Innovation," Pharmacoeconomics, 18 Suppl.1 (2000)

EXPUNGED

ClinicalTrials.gov entry for TRIUMPH trial, NCT00147199 (accessed April 20, 2018)

Declaration of Dean Bunce

United Therapeutics Corporation 2017 10-K, Part 1 of 2

United Therapeutics Corporation 2017 10-K, Part 2 of 2

EXPUNGED

EXPUNGED

Tyvaso Marketing Plan, December 2010, Internal, Part 2 of 4

Tyvaso Marketing Plan, December 2010, Internal, Part 3 of 4

Email from British Library regarding Voswinckel

Declaration of Ms. Pilar Wyman

Curriculum vitae of Pilar Wyman

Author & Subject Index for Circulation Supplement 17 (2004), Part 2 of 5

Author & Subject Index for Circulation Supplement 17 (2004), Part 3 of 5

Author & Subject Index for Circulation Supplement 17 (2004), Part 4 of 5

Declaration of Dr. Werner Seeger Accompanying Amendment and Reply filed in 13/469,854 dated August 20, 2015

Second Declaration of Dr. Werner Seeger

Second Declaration of Dr. Hossein A. Ghofrani

EXPUNGED

Bloomberg L.P. WACC Report for UTHR, 2003

McLaughlin V.V. et al., "Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension: A Randomized Controlled Clinical Trial," JACC, 18:1915-1922 (2010) (with appendix)

Author & Subject Index for Circulation Supplement 17 (2004), Part 1 of 5

Author & Subject Index for Circulation Supplement 17 (2004), Part 5 of 5

U.S. Application No. 60/800,016

LungRx TRIUMPH Executive Committee Meeting Agenda dated October 22, 2003

German language version of Ex. 1005 (also provided as Attachment 2d to Ex. 1013)

Patent Owner's Motion to File Under Seal

Services Agreement between Dr. Werner Seeger and LungRx dated Sept. 23, 2003

Joint Stipulation to Extend Time

Joint Stipulation to Extend Time

Exhibit 3005

DECISION Denying Patent Owner's Request for Rehearing

Patent Owner's Opposition to Petitioner's Combined Motion

Claims of Abandoned U.S. Application No. 11/748,205

EXPUNGED

Patent Owner's Updated Exhibit List

Patent Owner's Updated Exhibit List

Inventor Oaths filed in U.S. Application No. 12/591,200 (granted as the '240 patent) and U.S. Application No. 13/469,854 (granted as the '507 patent)

Dismissal of Complaint of Dr. Lewis Rubin and Motion for Attorney's Fees

Excerpts from Deposition of Dr. Lewis Rubin (public version)

Patent Owner's Motion to File Under Seal, 37 C.F.R. Section 42.54

Patent Owner's Notice of Deposition of Deforest McDuff, Ph.D. Under 37 C.F.R. Section 42.53

Patent Owner's Notice of Deposition of Maureen Donovan, Ph.D. Under 37 C.F.R. Section 42.53

Patent Owner Notice of Deposition of Scott Bennett

Ex. 1170 - Complaint in Rubin v. United Therapeutics Corp., No. 421672-V (Md. Cir. Ct. Apr. 3, 2017)

Ex. 1171 - Affidavit of Lewis J. Rubin in Rubin v. United Therapeutics Corp., No. 421672-V (Md. Cir. Ct. Nov. 14, 2017)

PETITIONERS' COMBINED MOTION TO SUBMIT SUPPLEMENTAL INFORMATION UNDER 37 C.F.R. section 42.123 AND MOTION FOR ADDITIONAL DISCOVERY UNDER 37 C.F.R. section 42.51

Ex. 1172 - Declaration of Rachel Turow in Support of Petition Under 37 C.F.R. section 1.47(a) filed in 11/748,205 (Nov. 30, 2007)

Order Conduct of the Proceeding

Correspondence Requests for Authorization

Patent Owner Reply to Petitioner's Response to Request for Rehearing Under 37 C.F.R. Section 42.71

Notice of Filing Transcript of February 23, 2018 Conference Call

Exhibit 2032

Patent Owner Updated Exhibit List

Order Conduct of the Proceeding

Ex. 3003

Petitioner's Response To Patent Owner's Request For Rehearing

Conduct of the Proceedings

Exhibit 3002

Order - Conduct of the Proceedings - 37 CFR 42.5

Ex. 3001

EXPUNGED

Ex. 1168 - Amendment and Reply Under 37 C.F.R. ¿¿ 1.111 in 13/469,854 (Jan. 4, 2013)

Ex. 1169 - Barrett, et. al., eds., Ganong's Review of Medical Physiology, 23rd ed. (2010) (excerpt)

Petitioner's First Set Of Objections To Patent Owner's Exhibits

Patent Owner Objections to Evidence

Ex. 1167 - DECLARATION OF KURT A. MATHAS IN SUPPORT OF MOTION FOR PHV ADMISSION

PETITIONER'S UPDATED EXHIBIT LIST (AS OF JANUARY 25, 2018)

PETITIONER'S MOTION FOR PHV ADMISSION OF KURT A. MATHAS

Patent Owner Request for Rehearing Under 37 C.F.R. Section 42.71

Decision Granting Institution of Inter Partes Review

Scheduling Order

Petitioner's Reply in Support of Petition

Order (June 21, 2016) (D.I. 48 in C.A. No. 3:15-cv-05723-PGS-LHG (D.N.J.)

Civil Docket for Case No. 3:15-cv-05723-PGS-LHG (D.N.J.) (accessed Nov. 8, 2017)

Exhibit 2031

Patent Owner Updated Exhibit List

Request for Rehearing of Decision Authorizing Petitioner's Reply to Patent Owner's Preliminary Response Under 37 C.F.R. Section 42.71

Exhibit 2001

Exhibit 2002

Exhibit 2004

Exhibit 2006

Exhibit 2014

Exhibit 2020

Exhibit 2027

Exhibit 2030

Patent Owner Preliminary Response

Exhibit 2003

Exhibit 2005

Exhibit 2007

Exhibit 2008

Exhibit 2009

Exhibit 2010

Exhibit 2011

Exhibit 2012

Exhibit 2013

Exhibit 2015

Exhibit 2016

Exhibit 2017

Exhibit 2018

Exhibit 2019

Exhibit 2021

Exhibit 2022

Exhibit 2023

Exhibit 2024

Exhibit 2025

Exhibit 2026

Exhibit 2028

Exhibit 2029

Notice of Accord Filing Date

Patent Owner's Mandatory Notices

Petitioner's Power of Attorney

U.S. Patent No. 9,339,507

Robert Voswinckel, et al. "Inhaled treprostinil sodium for the treatment of pulmonary hypertension" Abstract #1414, Circulation, 110, 17, Supplement (Oct. 2004): III-295 )

U.S. Patent Application Publication No. 2004/0265238 A1 to Chaudry

Hossein Ardeschi Ghofrani, Robert Voswinckel, et al., "Neue Therapieoptionen in der Behandlung der pulmonalarteriellen Hypertonie," Hertz, 30,4 (June 2005): 296-302

Opti-Neb-ir® Operating Instructions, Model ON-100/2 (2005)

Venta-Neb-ir® A-I-C-I Operating Instructions, Model VN-100/4

Annexes to Commission Decision C(2005)3436 of 05 September 2005, http://ec.europa.eu/health/documents/community-register/2005/2005090510259/anx_10259_en.pdf

U.S. Patent No. 6,606,989

Affidavit of Christopher Butler, June 15, 2017

Affidavit of Christopher Butler, June 16, 2017

U.S. Patent No. 6,521,212

Amendment and Reply Accompanying RCE filed in 12/591,200 (Jul. 2, 2013) (with accompanying Declaration of Lewis Rubin, M.D.)

WO 93/00951 to Patton

U.S. Patent No. 4,306,075

U.S. Patent No. 5,190,972

European Patent Specification 0347243 B1, published January 13, 1993

U.S. Patent No. 6,261,539

U.S. Patent No. 6,357,671

U.S. Patent No. 5,544,646

Edwards D.A. et al., Recent Advances in Pulmonary Drug Delivery Using Large Porous Inhaled Particles, Journal of Applied Physiology, 85(2): 379-385 (1998)

U.S. Food and Drug Administration, Drug Approval Package: Remodulin (approved on May 21, 2002), http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-272_Remodulin.cfm

EU Community Register of Medicinal Products, Homepage, http://ec.europa.eu/health/documents/community-register/html/index_en.htm

Muller et al., "Use of Inhaled Iloprost in a Case of Pulmonary Hypertension during Pediatric Congenital Heart Surgery," 99 Anesthesiology 743-747 (2003)

Commission Decision C(2005)3436 of 05 September 2005, http://ec.europa.eu/health/documents/community-register/2005/2005090510259/dec_10259_en.pdf

Electronic Medicines Compendium, Ventavis, http://www.medicines.org.uk/emc/history/13743#version1 (noting a change to section 4.2 - Posology and Method of Administration on September 22, 2005)

American Heart Association's Scientific Sessions 2004 - Largest Cardiovascular Meeting Plans to Jazz It Up in New Orleans, PR Newswire (Oct. 13 2004)

EU Community Register of Medicinal Products, Frequently Asked Questions, http://ec.europa.eu/health/documents/community-register/register_faq_2015.pdf

Register of Commission Documents, European Union, https://ec.europa.eu/transparency/regdoc/index.cfm?fuseaction=home

Regulation (EC) No. 1049/2001 of the European Parliament and of the Council of 30 May 2001, http://www.europarl.europa.eu/RegData/PDF/r1049_en.pdf

U.S. Patent No. 5,234,953

U.S. Patent No. 9,358,240

U.S. Patent No. 6,756,033

Amendment and Reply filed in 13/469,854 (Jan. 4, 2013) (with accompanying Declaration of Lewis Rubin, M.D.)

European Patent Application Publication No. EP 0372777 A2

U.S. Patent No. 4,895,719

U.S. Patent No. 5,153,222

Gessler, et al., Ultrasonic versus Jet Nebulization of Iloprost in Severe Pulmonary Hypertension, Eur. Respiratory J., 17:14-19 (2001)

Olschewski H., et al., Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension, 1996 Ann. Intern. Med. 124(9), 820-824 (1996)

Olschewski, et al., Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension, Chest J., 124(4), 1294-1304 (Oct. 2003)

Byron, Drug Delivery Devices: Issues in Drug Development, Proc. Am. Thorac. Soc., 1:321-328 (2004)

Badesch, et al., Prostanoid Therapy for Pulmonary Arterial Hypertension, J. of the Am. C. of Cardiology, 43(12):Suppl. S (2004)

U.S. Patent No. 6,054,486

Electronic Medicines Compendium, Ventavis, http://www.medicines.org.uk/emc/medicine/13743

European Agency Approves Ventavis for Primary Pulmonary Hypertension, P&T Community (Sep. 22, 2003), https://www.ptcommunity.com/news/2003-09-22-000000/european-agency-approves-ventavis-primary-pulmonary-hypertension

EMEA Scientific Discussion, Ventavis (2004), http://www.ema.europa.edu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000474/WC500048688.pdf

Mueller et al., "Inhaled Iloprost in the Management of Pulmonary Hypertension in Infants Undergoing Congenital Heart Surgery," 21 Eur. J. Anaesthesiology (suppl. 33) 2-36 (2004)

EU Community Register of Medicinal Products for Human Use, Ventavis, http://ec.europa.eu/health/documents/community-register/html/h255.htm#

Summary of Community Decisions, Official Journal of the European Union (Oct. 28, 2005)

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF

Register of the Commission Documents, European Commission

William F. Ganong, Review of Medical Physiology 591-92 (17th ed. 1995)

Actelion Pharmaceuticals, Annual Report, 2007

Reply in 13/469,854 (June 13, 2014)

Actelion Pharmaceuticals, "Actelion Announces Full Year 2003 Financial Results" (March 2, 2004)

Actelion Pharmaceuticals, "Actelion Announces Full Year 2005 Financial Results" (Feb. 23, 2006)

Actelion Pharmaceuticals, Annual Report, 2002

Actelion Pharmaceuticals, Annual Report, 2006

Actelion Pharmaceuticals, Annual Report, 2008

Actelion Pharmaceuticals, Annual Report, 2011

Actelion Pharmaceuticals, Annual Report, 2014

Actelion Pharmaceuticals, Annual Report, 2015

Adcirca, FDA Label, 5/2017

Adempas, FDA Label, 10/2016

Bayer, Annual Report, 2014

Bayer, Annual Report, 2015

Bayer, Annual Report, 2016

Highest paid female CEO: Race to save my daughter, CNBC (May 19, 2015), http://www.cnbc.com/2015/05/19/highestpaidfemaleceoracetosavemydaughter.html

Cowen and Company, Biotechnology Quarterly (Jan. 2011)

Cowen and Company, GlaxoSmithKline plc (Sep. 14, 2015)

Cowen and Company, GlaxoSmithKline plc, (May 16, 2016)

Cowen and Company, Therapeutic Categories Outlook, Feb. 2017

Approved Drug Products with Therapeutic Equivalance Evaluations ("Orange Book"), FDA (37th ed. 2017)

Actelion Pharmaceuticals, Annual Report, 2010

Actelion Pharmaceuticals, Annual Report, 2012

Actelion Pharmaceuticals, Annual Report, 2013

Actelion Pharmaceuticals, Annual Report, 2016

DiMasi, Joseph A. and Henry G. Grabowski (2012), "R&D Costs and Returns to New Drug Development: A Review of the Evidence," in Patricia Danzen and Sean Nicholson, ed.

Approved Drug Products with Therapeutic Equivalance Evaluations ("Orange Book"), FDA (30th ed. 2010)

FDA Drug Details Website, Adempas, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Opsumit, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Revatio, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Tracleer, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Tyvaso, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Veletri, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

Gilead, Form 10-K, 2009

Gilead, Form 10-K, 2010

Gilead, Form 10K, 2011

Gilead, Form 10K, 2014

FDA Drug Details Website, Adcirca, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Letairis, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Orenitram, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Remodulin, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Uptravi, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

FDA Drug Details Website, Ventavis, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

Federal Reserve Website, Data Download, CHF to USD, 1998-2016, https://www.federalreserve.gov/datadownload/Preview.aspx?pi=400&rel=H10&preview=H10/ H10/RXI_N.A.SZ (accessed 4/25/2017)

Federal Reserve Website, Data Download, USD to EUR, 1999-2016, https://www.federalreserve.gov/datadownload/Preview.aspx?pi=400&rel=H10&preview=H10/ H10/RXI$US_N.A.EU (accessed 4/25/2017)

Federal Reserve Website, Data Download, USD to GBP, 1998-2016, https://www.federalreserve.gov/datadownload/Preview.aspx?pi=400&rel=H10&preview=H10/ H10/RXI$US_N.A.UK (accessed 4/25/2017)

Flolan, FDA Label, 4/2015

Gilead, Form 10K, 2012

Gilead, Form 10K, 2013

Gilead, Form 10K, 2015

Gilead, Form 10K, 2016

1112 GlaxoWellcome, Annual Report, 1997

Grabowski, Henry, John Vernon, and Joseph A. DiMasi (2002), Returns on Research and Development for 1990s New Drug Introductions, Pharmacoeconomics 20(3): 11-29

GSK, Annual Report, 2010

GSK, Annual Report, 2011

GSK, Annual Report, 2013

Letairis, FDA Label, 10/2015

Mayo Clinic Website, Pulmonary hypertension, Overview, http://www.mayoclinic.org/diseasesconditions/ pulmonary-hypertension/home/ovc-20197480 (accessed 3/22/2017)

Merck & Co. v. Teva Pharmaceuticals USA, Inc., 395 F.3d 1364 (Fed. Cir. 2005)

Opsumit, FDA Label, 3/2017

Orenitram, FDA Label, 1/2017

Pfizer, Annual Report, 2009

Pfizer, Annual Report, 2015

RBC Capital Markets, Untied Therapeutics Corp., 6/13/2011

Remodulin, FDA Label, 12/2014

Tracleer, FDA Label, 10/2016

Tyvaso, FDA Label, 06/2016

GSK, Annual Report, 2012

GSK, Annual Report, 2016

NIH Website; National Heart, Lung, and Blood Institute; Types of Pulmonary Hypertension, https://www.nhlbi.nih.gov/health/health-topics/topics/pah/types (accessed 5/16/2017)

Pfizer, Annual Report, 2005

Pfizer, Annual Report, 2010

Pfizer, Annual Report, 2011

Pfizer, Annual Report, 2012

Pfizer, Annual Report, 2013

Pfizer, Annual Report, 2014

Pfizer, Annual Report, 2016

Revatio, FDA Label, 4/2015

Uptravi, FDA Label, 12/2015

UTC, Form 10-K, 2000

UTC, Form 10-K, 2002

UTC, Q2 2010 United Therapeutics Earnings Conference Call, 7/28/2010

UTC, Form 10K, 2006

UTC, Form 10K, 2011

UTC, Form 10K, 2012

UTC, Form 10K, 2013

UTC, Form 10K, 2015

Veletri, FDA Label, 6/2012

Ventavis, FDA Label, 11/2013

Reply filed in 13/469,854 (June 13, 2014)

Final Rejection of 13/469,854 (Mar. 13, 2014)

UTC, Form 10K, 2003

UTC, Form 10K, 2004

UTC, Form 10K, 2005

UTC, Form 10K, 2007

UTC, Form 10K, 2008

UTC, Form 10K, 2009

UTC, Form 10K, 2010

UTC, Form 10K, 2014

UTC, Form 10K, 2016

Substantive Submission filed in 12/591,200 (Nov. 9, 2015) (with accompanying Declaration of Dr. Roham T. Zamanian)

Amendment and Reply filed in 12/591,200 (Feb. 2, 2016) (with accompanying Second Declaration of Dr. Roham T. Zamanian)

Voswinckel, R., et al., Inhaled treprostinil is a potent pulmonary vasodilator in severe pulmonary hypertension, 25 European Heart Journal 22, at 218 (2004)

Sulica, R and Poon, M. Medical Therapeutics for Pulmonary Arterial Hypertension From Basic Science and Clinical Trial Design to Evidence-Based Medicine. 3(2) Expert Rev. Cardiovas. Ther. 347-360 (2005)

Declaration of DeForest McDuff, Ph.D.

Pfizer, Annual Report, 2006

FDA Drug Details Website, Flolan, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 5/17/2017)

St. Louis Federal Reserve, Consumer Price Index, https://fred.stlouisfed.org/series/CPIAUCSL (accessed 5/17/2017)

Declaration of Scott Bennett, Ph.D. Part 1/2

Declaration of Scott Bennett, Ph.D. Part 2/2

Declaration of Maureen D. Donovan in Support of the Petition for Inter Partes Review of U.S. Patent No. 9,339,507

PETITION FOR INTER PARTES REVIEW '507